It may because high levels of PD-L1 expressed on cancer cells and/or in TME in these types of cancer and therefore respond well to immunotherapy, which works by blocking the interaction between PD-L1 and PD-1 on T-cells. The gene discussed is PDCD1; the disease is cancer.